AbbVie’s $63B Allergan buyout offer depends on Botox growth. But will it last?

An enduring medical aesthetics franchise, led by wrinkle-fighter Botox, is one of the key reasons AbbVie is shelling out $63 billion for Allergan. That drug has again pulled off a sales jump, though a slower growth rate suggests a tough game ahead.